Product: NFAT2 Antibody
Catalog: DF6446
Description: Rabbit polyclonal antibody to NFAT2
Application: WB IHC IF/ICC
Reactivity: Human, Mouse, Rat
Prediction: Pig, Bovine, Horse, Rabbit
Mol.Wt.: 78,101kDa; 101kD(Calculated).
Uniprot: O95644
RRID: AB_2838409

View similar products>>

   Size Price Inventory
 100ul $280 In stock
 200ul $350 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors

Product Info

Source:
Rabbit
Application:
IF/ICC 1:100-1:500, WB 1:500-1:2000, IHC 1:50-1:200
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Reactivity:
Human,Mouse,Rat
Prediction:
Pig(88%), Bovine(88%), Horse(88%), Rabbit(100%)
Clonality:
Polyclonal
Specificity:
NFAT2 Antibody detects endogenous levels of total NFAT2.
RRID:
AB_2838409
Cite Format: Affinity Biosciences Cat# DF6446, RRID:AB_2838409.
Conjugate:
Unconjugated.
Purification:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
Storage:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
Alias:

Fold/Unfold

cytoplasmic 1; MGC138448; NF ATc; NF ATc1; NF-ATc; NF-ATc1; NF-ATc1.2; NFAC1_HUMAN; NFAT 2; NFAT transcription complex cytosolic component; NFATC 1; NFATc; NFATc1; Nuclear factor of activated T cells cytoplasmic 1; Nuclear factor of activated T cells cytoplasmic calcineurin dependent 1; Nuclear factor of activated T cells cytosolic component 1; nuclear factor of activated T-cells 'c'; Nuclear factor of activated T-cells;

Immunogens

Immunogen:
Uniprot:
Gene(ID):
Expression:
O95644 NFAC1_HUMAN:

Expressed in thymus, peripheral leukocytes as T-cells and spleen. Isoforms A are preferentially expressed in effector T-cells (thymus and peripheral leukocytes) whereas isoforms B and isoforms C are preferentially expressed in naive T-cells (spleen). Isoforms B are expressed in naive T-cells after first antigen exposure and isoforms A are expressed in effector T-cells after second antigen exposure. Isoforms IA are widely expressed but not detected in liver nor pancreas, neural expression is strongest in corpus callosum. Isoforms IB are expressed mostly in muscle, cerebellum, placenta and thymus, neural expression in fetal and adult brain, strongest in corpus callosum.

Description:
The NFAT (nuclear factor of activated T cells) family of proteins consists of NFAT1 (NFATc2 or NFATp), NFAT2 (NFATc1 or NFATc), NFAT3 (NFATc4), and NFAT4 (NFATc3 or NFATx). All members of this family are transcription factors with a Rel homology domain and regulate gene transcription in concert with AP-1 (Jun/Fos) to orchestrate an effective immune response (1,2). NFAT proteins are predominantly expressed in cells of the immune system, but are also expressed in skeletal muscle, keratinocytes, and adipocytes, regulating cell differentiation programs in these cells (3). In resting cells, NFAT proteins are heavily phosphorylated and localized in the cytoplasm. Increased intracellular calcium concentrations activate the calcium/calmodulin-dependent serine phosphatase calcineurin, which dephosphorylates NFAT proteins, resulting in their subsequent translocation to the nucleus (2). Termination of NFAT signaling occurs upon declining calcium concentrations and phosphorylation of NFAT by kinases such as GSK-3 or CK1 (3,4). Cyclosporin A and FK506 are immunosuppressive drugs that inhibit calcineurin and thus retain NFAT proteins in the cytoplasm (5).
Sequence:
MPSTSFPVPSKFPLGPAAAVFGRGETLGPAPRAGGTMKSAEEEHYGYASSNVSPALPLPTAHSTLPAPCHNLQTSTPGIIPPADHPSGYGAALDGGPAGYFLSSGHTRPDGAPALESPRIEITSCLGLYHNNNQFFHDVEVEDVLPSSKRSPSTATLSLPSLEAYRDPSCLSPASSLSSRSCNSEASSYESNYSYPYASPQTSPWQSPCVSPKTTDPEEGFPRGLGACTLLGSPRHSPSTSPRASVTEESWLGARSSRPASPCNKRKYSLNGRQPPYSPHHSPTPSPHGSPRVSVTDDSWLGNTTQYTSSAIVAAINALTTDSSLDLGDGVPVKSRKTTLEQPPSVALKVEPVGEDLGSPPPPADFAPEDYSSFQHIRKGGFCDQYLAVPQHPYQWAKPKPLSPTSYMSPTLPALDWQLPSHSGPYELRIEVQPKSHHRAHYETEGSRGAVKASAGGHPIVQLHGYLENEPLMLQLFIGTADDRLLRPHAFYQVHRITGKTVSTTSHEAILSNTKVLEIPLLPENSMRAVIDCAGILKLRNSDIELRKGETDIGRKNTRVRLVFRVHVPQPSGRTLSLQVASNPIECSQRSAQELPLVEKQSTDSYPVVGGKKMVLSGHNFLQDSKVIFVEKAPDGHHVWEMEAKTDRDLCKPNSLVVEIPPFRNQRITSPVHVSFYVCNGKRKRSQYQRFTYLPANVPIIKTEPTDDYEPAPTCGPVSQGLSPLPRPYYSQQLAMPPDPSSCLVAGFPPCPQRSTLMPAAPGVSPKLHDLSPAAYTKGVASPGHCHLGLPQPAGEAPAVQDVPRPVATHPGSPGQPPPALLPQQVSAPPSSSCPPGLEHSLCPSSPSPPLPPATQEPTCLQPCSPACPPATGRPQHLPSTVRRDESPTAGPRLLPEVHEDGSPNLAPIPVTVKREPEELDQLYLDDVNEIIRNDLSSTSTHS

Predictions

Predictions:

Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Species
Results
Score
Rabbit
100
Pig
88
Horse
88
Bovine
88
Dog
75
Xenopus
75
Zebrafish
75
Chicken
75
Sheep
71
Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

PTMs - O95644 As Substrate

Site PTM Type Enzyme
R23 Methylation
S117 Phosphorylation
S151 Phosphorylation
S158 Phosphorylation
S161 Phosphorylation
S169 Phosphorylation
S172 Phosphorylation P27361 (MAPK3) , Q16539 (MAPK14) , P45983 (MAPK8) , P53779 (MAPK10)
S175 Phosphorylation
S176 Phosphorylation
S178 Phosphorylation
S179 Phosphorylation
S181 Phosphorylation
S184 Phosphorylation
S187 Phosphorylation
Y197 Phosphorylation
S211 Phosphorylation
S233 Phosphorylation
S237 Phosphorylation
S241 Phosphorylation
S245 Phosphorylation P17612 (PRKACA)
S250 Phosphorylation
S257 Phosphorylation
S261 Phosphorylation
S269 Phosphorylation P17612 (PRKACA)
S278 Phosphorylation
S282 Phosphorylation
S286 Phosphorylation
S290 Phosphorylation
S294 Phosphorylation P17252 (PRKCA) , P17612 (PRKACA)
S324 Phosphorylation
K337 Ubiquitination
S345 Phosphorylation
K349 Sumoylation
S359 Phosphorylation
Y371 Phosphorylation P52333 (JAK3)
K379 Ubiquitination
Y386 Phosphorylation
Y394 Phosphorylation
K398 Ubiquitination
S403 Phosphorylation
S409 Phosphorylation
Y426 Phosphorylation
T504 Phosphorylation
S512 Phosphorylation
S526 Phosphorylation
K538 Ubiquitination
S542 Phosphorylation
K548 Ubiquitination
K612 Acetylation
K626 Acetylation
S670 Phosphorylation
K702 Sumoylation
Y709 Phosphorylation
S765 Phosphorylation
S772 Phosphorylation
S813 Phosphorylation
S887 Phosphorylation
S903 Phosphorylation
T912 Phosphorylation
K914 Sumoylation

Research Backgrounds

Function:

Plays a role in the inducible expression of cytokine genes in T-cells, especially in the induction of the IL-2 or IL-4 gene transcription. Also controls gene expression in embryonic cardiac cells. Could regulate not only the activation and proliferation but also the differentiation and programmed death of T-lymphocytes as well as lymphoid and non-lymphoid cells. Required for osteoclastogenesis and regulates many genes important for osteoclast differentiation and function (By similarity).

PTMs:

Phosphorylated by NFATC-kinase and GSK3B; phosphorylation induces NFATC1 nuclear exit and dephosphorylation by calcineurin promotes nuclear import. Phosphorylation by PKA and DYRK2 negatively modulates nuclear accumulation, and promotes subsequent phosphorylation by GSK3B or casein kinase 1.

Subcellular Location:

Cytoplasm. Nucleus.
Note: Cytoplasmic for the phosphorylated form and nuclear after activation that is controlled by calcineurin-mediated dephosphorylation. Rapid nuclear exit of NFATC is thought to be one mechanism by which cells distinguish between sustained and transient calcium signals. The subcellular localization of NFATC plays a key role in the regulation of gene transcription (PubMed:16511445). Nuclear translocation of NFATC1 is enhanced in the presence of TNFSF11. Nuclear translocation is decreased in the presence of FBN1 which can bind and sequester TNFSF11 (By similarity).

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
Tissue Specificity:

Expressed in thymus, peripheral leukocytes as T-cells and spleen. Isoforms A are preferentially expressed in effector T-cells (thymus and peripheral leukocytes) whereas isoforms B and isoforms C are preferentially expressed in naive T-cells (spleen). Isoforms B are expressed in naive T-cells after first antigen exposure and isoforms A are expressed in effector T-cells after second antigen exposure. Isoforms IA are widely expressed but not detected in liver nor pancreas, neural expression is strongest in corpus callosum. Isoforms IB are expressed mostly in muscle, cerebellum, placenta and thymus, neural expression in fetal and adult brain, strongest in corpus callosum.

Subunit Structure:

Member of the multicomponent NFATC transcription complex that consists of at least two components, a pre-existing cytoplasmic component NFATC2 and an inducible nuclear component NFATC1. Other members such as NFATC4, NFATC3 or members of the activating protein-1 family, MAF, GATA4 and Cbp/p300 can also bind the complex. NFATC proteins bind to DNA as monomers. Interacts with HOMER2 and HOMER3; this interaction may compete with calcineurin/PPP3CA-binding and hence prevent NFATC1 dephosphorylation and activation.

Family&Domains:

Rel Similarity Domain (RSD) allows DNA-binding and cooperative interactions with AP1 factors.

The N-terminal transactivation domain (TAD-A) binds to and is activated by Cbp/p300. The dephosphorylated form contains two unmasked nuclear localization signals (NLS), which allow translocation of the protein to the nucleus.

Isoforms C have a C-terminal part with an additional trans-activation domain, TAD-B, which acts as a transcriptional activator. Isoforms B have a shorter C-terminal part without complete TAD-B which acts as a transcriptional repressor.

Research Fields

· Cellular Processes > Cell growth and death > Cellular senescence.   (View pathway)

· Environmental Information Processing > Signal transduction > MAPK signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > cGMP-PKG signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > cAMP signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > Wnt signaling pathway.   (View pathway)

· Human Diseases > Infectious diseases: Viral > Hepatitis B.

· Human Diseases > Infectious diseases: Viral > HTLV-I infection.

· Human Diseases > Immune diseases > Inflammatory bowel disease (IBD).

· Organismal Systems > Development > Osteoclast differentiation.   (View pathway)

· Organismal Systems > Immune system > Natural killer cell mediated cytotoxicity.   (View pathway)

· Organismal Systems > Immune system > Th1 and Th2 cell differentiation.   (View pathway)

· Organismal Systems > Immune system > Th17 cell differentiation.   (View pathway)

· Organismal Systems > Immune system > T cell receptor signaling pathway.   (View pathway)

· Organismal Systems > Immune system > B cell receptor signaling pathway.   (View pathway)

· Organismal Systems > Endocrine system > Oxytocin signaling pathway.

References

1). Ultrasmall PtAu2 nanoclusters activate endogenous anti-inflammatory and anti-oxidative systems to prevent inflammatory osteolysis. Theranostics, 2023 (PubMed: 36793859) [IF=12.4]

2). Sustained delivery of growth factors and alendronate using partially demineralized dentin matrix for endogenous periodontal regeneration. Applied Materials Today, 2021 [IF=8.3]

3). Diterbutyl phthalate attenuates osteoarthritis in ACLT mice via suppressing ERK/c-fos/NFATc1 pathway, and subsequently inhibiting subchondral osteoclast fusion. ACTA PHARMACOLOGICA SINICA, 2022 (PubMed: 34381182) [IF=8.2]

4). Structure-based virtual screening for discovery of paederosidic acid from Paederia scandens as novel P2Y14R antagonist. Phytomedicine : international journal of phytotherapy and phytopharmacology, 2023 (PubMed: 37149963) [IF=7.9]

5). Mussel-inspired multifunctional surface through promoting osteogenesis and inhibiting osteoclastogenesis to facilitate bone regeneration. npj Regenerative Medicine, 2022 (PubMed: 35562356) [IF=7.2]

Application: IF/ICC    Species: Mouse    Sample: BMMs

Fig. 6 In vitro osteoclastic differentiation behaviors of BMMs after different treatments. Representative a TRAP staining and b F-actin ring staining assays for BMMs incubated with different scaffold extracts. The white arrows indicate the representative sealing zone of osteoclasts. Quantitative analysis of c TRAP staining and d F-actin rings in different groups. e The expression of osteoclastogenesis-related genes, including NFATc1, CTSK, and RANK, as determined by qRT–PCR assay. Representative immunofluorescent staining images of f NFATc1 (green), g CTSK (green), and h RANK (green) in BMMs incubated with different extracts. F-actin and cell nuclei were labeled with fluorescent red and blue, respectively. Images were captured using confocal microscopy. This suggested that the newly developed LYN-containing scaffolds may inhibit the osteoclastic differentiation of BMMs by sustaining the supply of LYN. Scale bar in a: 50 μm, in b: 200 μm, in f–h: 25 μm. Data are expressed as the mean ± SD (n = 3). *P < 0.05 and **P < 0.01 indicate significant differences compared with the control group. #P < 0.05 and # #P < 0.01 indicate significant differences compared with the HS@PDA-LYN/HA group.

6). Trimethylamine-N-Oxide Promotes Osteoclast Differentiation and Bone Loss via Activating ROS-Dependent NF-κB Signaling Pathway. Nutrients, 2022 (PubMed: 36235607) [IF=5.9]

Application: WB    Species: Mouse    Sample:

Figure 3. TMAO enhanced osteoclast gene expression and the NF-κB signaling pathway. (A) TMAO enhanced osteoclast gene expression (n = 3 per group) as examined by real-time PCR. (B,C) TMAO enhanced c-Fos and NFATc1 protein expression as evaluated by Western blot (n = 3 per group). (D,E) The protein expression levels of p-IKK, IKK, p-IκBα, IκBα, p-p65, and p65 were examined by Western blot after TMAO treatment. TMAO increased RANKL-stimulated phosphorylation of IKK, IκBα, and p65 (n = 3 per group).

7). Huangkui Capsule Ameliorates Renal Fibrosis in a Unilateral Ureteral Obstruction Mouse Model Through TRPC6 Dependent Signaling Pathways. Frontiers in Pharmacology, 2020 (PubMed: 32719603) [IF=5.6]

Application: WB    Species: mouse    Sample: Kidney

FIGURE 6 | HKC suppresses TRPC6/CnA/NFAT expression in UUO mice. Representative western blots and quantification of the levels of TRPC6 (A), CnA (B) as well as NFAT (C) in sham, and UUO mice with different treatments. GAPDH was used as an internal control. ##P < 0.01, UUO group vs. sham group; *P < 0.05, **P < 0.01, UUO +HKC group vs. UUO group. Bar graphs represent the mean ± SEM (n = 3).

8). Suppression of TLR4 prevents diabetic bone loss by regulating FTO-mediated m6A modification. International immunopharmacology, 2023 (PubMed: 37413932) [IF=5.6]

9). Dehydromiltirone inhibits osteoclast differentiation in RAW264.7 and bone marrow macrophages by modulating MAPK and NF-κB activity. Frontiers in Pharmacology, 2022 (PubMed: 36210855) [IF=5.6]

10). Plastrum testudinis extract suppresses osteoclast differentiation via the NF-κB signaling pathway and ameliorates senile osteoporosis. Journal of ethnopharmacology, 2021 (PubMed: 33974944) [IF=5.4]

Load more

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.